1
|
Laurent-Bellue A, Sadraoui A, Claude L, Calderaro J, Posseme K, Vibert E, Cherqui D, Rosmorduc O, Lewin M, Pesquet JC, Guettier C. Deep Learning Classification and Quantification of Pejorative and Nonpejorative Architectures in Resected Hepatocellular Carcinoma from Digital Histopathologic Images. THE AMERICAN JOURNAL OF PATHOLOGY 2024; 194:1684-1700. [PMID: 38879083 DOI: 10.1016/j.ajpath.2024.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 04/17/2024] [Accepted: 05/16/2024] [Indexed: 06/27/2024]
Abstract
Liver resection is one of the best treatments for small hepatocellular carcinoma (HCC), but post-resection recurrence is frequent. Biotherapies have emerged as an efficient adjuvant treatment, making the identification of patients at high risk of recurrence critical. Microvascular invasion (mVI), poor differentiation, pejorative macrotrabecular architectures, and vessels encapsulating tumor clusters architectures are the most accurate histologic predictors of recurrence, but their evaluation is time-consuming and imperfect. Herein, a supervised deep learning-based approach with ResNet34 on 680 whole slide images (WSIs) from 107 liver resection specimens was used to build an algorithm for the identification and quantification of these pejorative architectures. This model achieved an accuracy of 0.864 at patch level and 0.823 at WSI level. To assess its robustness, it was validated on an external cohort of 29 HCCs from another hospital, with an accuracy of 0.787 at WSI level, affirming its generalization capabilities. Moreover, the largest connected areas of the pejorative architectures extracted from the model were positively correlated to the presence of mVI and the number of tumor emboli. These results suggest that the identification of pejorative architectures could be an efficient surrogate of mVI and have a strong predictive value for the risk of recurrence. This study is the first step in the construction of a composite predictive algorithm for early post-resection recurrence of HCC, including artificial intelligence-based features.
Collapse
Affiliation(s)
- Astrid Laurent-Bellue
- Department of Pathology, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France
| | - Aymen Sadraoui
- Centre de Vision Numérique, Paris-Saclay University, Inria, CentraleSupélec, Gif-sur-Yvette, France
| | - Laura Claude
- Department of Pathology, Charles Nicolle Hospital, Rouen, France
| | - Julien Calderaro
- Department of Pathology, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Katia Posseme
- Department of Pathology, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France
| | - Eric Vibert
- Centre Hépato-Biliaire, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Villejuif, France; Faculté de Médecine, Paris-Saclay University, Le Kremlin-Bicêtre, France; Unité Mixte de Recherche 1193, Paris-Saclay University, INSERM, Villejuif, France
| | - Daniel Cherqui
- Centre Hépato-Biliaire, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Villejuif, France; Faculté de Médecine, Paris-Saclay University, Le Kremlin-Bicêtre, France; Unité Mixte de Recherche 1193, Paris-Saclay University, INSERM, Villejuif, France
| | - Olivier Rosmorduc
- Centre Hépato-Biliaire, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Villejuif, France; Faculté de Médecine, Paris-Saclay University, Le Kremlin-Bicêtre, France; Unité Mixte de Recherche 1193, Paris-Saclay University, INSERM, Villejuif, France
| | - Maïté Lewin
- Centre Hépato-Biliaire, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Villejuif, France; Faculté de Médecine, Paris-Saclay University, Le Kremlin-Bicêtre, France; Unité Mixte de Recherche 1193, Paris-Saclay University, INSERM, Villejuif, France
| | - Jean-Christophe Pesquet
- Centre de Vision Numérique, Paris-Saclay University, Inria, CentraleSupélec, Gif-sur-Yvette, France
| | - Catherine Guettier
- Department of Pathology, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
| |
Collapse
|
2
|
Fuster-Anglada C, Mauro E, Ferrer-Fàbrega J, Caballol B, Sanduzzi-Zamparelli M, Bruix J, Fuster J, Reig M, Díaz A, Forner A. Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol 2024:S0168-8278(24)02324-9. [PMID: 38925272 DOI: 10.1016/j.jhep.2024.06.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 06/11/2024] [Accepted: 06/17/2024] [Indexed: 06/28/2024]
Abstract
BACKGROUND & AIMS Assessment of recurrence risk after liver resection (LR) is critical in hepatocellular carcinoma (HCC), particularly with the advent of effective adjuvant therapy. The aim of this study was to analyze the clinical and pathological factors associated with recurrence, aggressive recurrence, and survival after LR. METHOD We performed a retrospective study in which all single HCC (BCLC-0/A) patients treated with LR between February 2000 and November 2020 were included. The main clinical variables were recorded. Histological features were blindly evaluated by two independent pathologists. Aggressive recurrence was defined as those that exceeded the Milan criteria at 1st recurrence. RESULTS A total of 218 patients were included (30% BCLC 0 and 70% BCLC A), median (IQR) tumor size of 28 (19-42 mm). The prevalence of microvascular invasion and/or satellitosis (mVI/S) was 39%, with a kappa-index between both pathologists of 0.8. After a median follow-up of 49 (23-85) months, 61/218 (28%) patients died, 32/218 (15%) underwent liver transplantation, 127 (58%) developed HCC recurrence. The prevalence of aggressive recurrence was 35% (44/127 Milan-out, with 20 cases at advanced stage), and the 5-year survival rate was 81%. The presence of mVI/S was the only independent predictor of recurrence (hazard ratio [HR] 1.83, 95% CI 1.28-2.61, p <0.001), aggressive recurrence (HR 3.31, 95% CI 1.74-6.29, p <0.001) and mortality (HR 2.23, 95% CI 1.27-3.91, p = 0.005). The macrotrabecular-massive subtype was significantly associated with a higher prevalence of mVI/S, Edmonson Steiner grade III-IV, AFP values and vessels that encapsulate tumor clusters, but not with recurrence, aggressive recurrence, or overall survival. CONCLUSION The presence of mVI/S was the only independent risk factor for aggressive recurrence and mortality. This has important implications for early-stage patient management, especially in the setting of adjuvant immunotherapy or ab initio LT. IMPACT AND IMPLICATIONS Assessment of recurrence risk after liver resection is crucial in patients with hepatocellular carcinoma. Patients with a high risk of recurrence are candidates for liver transplantation as an ab initio indication or for the potential use of adjuvant therapy. Aggressive recurrences, defined as those exceeding the Milan criteria at first recurrence, have a significant impact on overall survival (OS). Fifty-eight percent of patients experienced hepatocellular carcinoma recurrence, with a prevalence of aggressive recurrence at the first occurrence standing at 35%. After a median follow-up of 49 (23-85) months, 61 (28%) patients died, and 32 (15%) underwent liver transplantation, resulting in a 5-year OS rate of 81%. Microvascular invasion and/or satellitosis was present in 39% of our cohort and was the only independent predictor of recurrence, aggressive recurrence, and OS on multivariate analysis. This is important as it could be used to guide therapeutic management.
Collapse
Affiliation(s)
- Carla Fuster-Anglada
- Pathology Department. CDB. Liver Oncology Unit. Hospital Clinic Barcelona. Barcelona. Spain; Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain
| | - Ezequiel Mauro
- Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Liver Unit. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona, Spain
| | - Joana Ferrer-Fàbrega
- Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Hepatobiliopancreatic Surgery and Liver and Pancreatic Transplantation Unit, Department of Surgery. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona. Spain; Universitat de Barcelona, Barcelona, Spain
| | - Berta Caballol
- Liver Unit. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona, Spain
| | - Marco Sanduzzi-Zamparelli
- Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Liver Unit. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona, Spain
| | - Jordi Bruix
- Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Universitat de Barcelona, Barcelona, Spain; Liver Unit. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona, Spain
| | - Josep Fuster
- Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Hepatobiliopancreatic Surgery and Liver and Pancreatic Transplantation Unit, Department of Surgery. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona. Spain; Universitat de Barcelona, Barcelona, Spain
| | - María Reig
- Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Universitat de Barcelona, Barcelona, Spain; Liver Unit. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona, Spain
| | - Alba Díaz
- Pathology Department. CDB. Liver Oncology Unit. Hospital Clinic Barcelona. Barcelona. Spain; Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Universitat de Barcelona, Barcelona, Spain.
| | - Alejandro Forner
- Barcelona Clinic Liver Cancer (BCLC) group. IDIBAPS. Barcelona. Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; Universitat de Barcelona, Barcelona, Spain; Liver Unit. Liver Oncology Unit. ICMDM. Hospital Clinic Barcelona. Barcelona, Spain.
| |
Collapse
|
3
|
Xu W, Huang B, Zhang R, Zhong X, Zhou W, Zhuang S, Xie X, Fang J, Xu M. Diagnostic and Prognostic Ability of Contrast-Enhanced Unltrasound and Biomarkers in Hepatocellular Carcinoma Subtypes. ULTRASOUND IN MEDICINE & BIOLOGY 2024; 50:617-626. [PMID: 38281888 DOI: 10.1016/j.ultrasmedbio.2024.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 10/07/2023] [Accepted: 01/06/2024] [Indexed: 01/30/2024]
Abstract
OBJECTIVE To investigate the diagnostic and prognostic value of contrast-enhanced ultrasound (CEUS) and clinical indicators of the vessels encapsulating tumor clusters (VETC) pattern and macrotrabecular-massive subtype in hepatocellular carcinoma (MTM-HCC). METHODS This retrospective study included patients who underwent preoperative CEUS and hepatectomy for HCC between August 2018 and August 2021. Multivariable logistic regression was performed to select independent correlated factors of VETC-HCC and MTM-HCC to develop nomogram models. The association between model outcomes and early postoperative HCC recurrence was assessed using Kaplan-Meier curve and Cox regression analysis. RESULTS The training cohort included 182 patients (54.3 ± 11.3 years, 168 males) and the validation cohort included 91 patients (54.8 ± 10.6 years, 81 males). Multivariate logistic regression analysis revealed that α-fetoprotein (AFP) levels (odds ratio [OR]: 2.26, 95% confidence interval [CI]: 1.49-3.42, p < 0.001), intratumoral nonenhancement (OR: 2.40, 95% CI: 1.02-5.64, p = 0.044), and the perfusion pattern in the CEUS arterial phase (OR: 2.27, 95% CI: 1.05-4.91, p = 0.038) were independent predictors of VETC-HCC. Besides, the former two were also independently associated with MTM-HCC (AFP level: OR: 2.36, 95% CI: 1.36-4.09, p = 0.002; intratumoral nonenhancement: OR: 3.72, 95% CI: 1.02-13.56, p = 0.046). Nomogram models were constructed based on the aforementioned indicators. Kaplan-Meier curve analysis indicated that predicted VETC-HCC or MTM-HCC exhibited higher rates of early recurrence (log-rank p < 0.001 and p = 0.002, respectively). Cox regression analysis showed that a high risk of VETC-HCC was independently correlated with early recurrence (p = 0.011). CONCLUSION CEUS combined with AFP levels can predict VETC-HCC/MTM-HCC and prognosis preoperatively.
Collapse
Affiliation(s)
- Wenxin Xu
- Department of Medical Ultrasonics, The First Affiliated Hospital, Institute of Diagnostic and Interventional Ultrasound, Sun Yat-Sen University, Guangzhou, China
| | - Biyu Huang
- Key Laboratory of Gene Function and Regulation, School of Life Sciences, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China
| | - Rui Zhang
- Department of Medical Ultrasonics, The First Affiliated Hospital, Institute of Diagnostic and Interventional Ultrasound, Sun Yat-Sen University, Guangzhou, China
| | - Xian Zhong
- Department of Medical Ultrasonics, The First Affiliated Hospital, Institute of Diagnostic and Interventional Ultrasound, Sun Yat-Sen University, Guangzhou, China
| | - Wenwen Zhou
- Department of Medical Ultrasonics, The First Affiliated Hospital, Institute of Diagnostic and Interventional Ultrasound, Sun Yat-Sen University, Guangzhou, China
| | - Shimei Zhuang
- Key Laboratory of Gene Function and Regulation, School of Life Sciences, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China
| | - Xiaoyan Xie
- Department of Medical Ultrasonics, The First Affiliated Hospital, Institute of Diagnostic and Interventional Ultrasound, Sun Yat-Sen University, Guangzhou, China
| | - Jianhong Fang
- Key Laboratory of Gene Function and Regulation, School of Life Sciences, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China
| | - Ming Xu
- Department of Medical Ultrasonics, The First Affiliated Hospital, Institute of Diagnostic and Interventional Ultrasound, Sun Yat-Sen University, Guangzhou, China.
| |
Collapse
|
4
|
Amory B, Goumard C, Laurent A, Langella S, Cherqui D, Salame E, Barbier L, Soubrane O, Farges O, Hobeika C, Kawai T, Regimbeau JM, Faitot F, Pessaux P, Truant S, Boleslawski E, Herrero A, Mabrut JY, Chiche L, Di Martino M, Rhaiem R, Schwarz L, Resende V, Calderaro J, Augustin J, Caruso S, Sommacale D, Hofmeyr S, Ferrero A, Fuks D, Vibert E, Torzilli G, Scatton O, Brustia R. Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching. Surgery 2024; 175:413-423. [PMID: 37981553 DOI: 10.1016/j.surg.2023.09.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 09/06/2023] [Accepted: 09/26/2023] [Indexed: 11/21/2023]
Abstract
BACKGROUND Combined hepatocholangiocarcinoma is a rare cancer with a grim prognosis composed of both hepatocellular carcinoma and intrahepatic cholangiocarcinoma morphologic patterns in the same tumor. The aim of this multicenter, international cohort study was to compare the oncologic outcomes after surgery of combined hepatocholangiocarcinoma to hepatocellular carcinoma and intrahepatic cholangiocarcinoma. METHODS Patients treated by surgery for combined hepatocholangiocarcinoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma from 2000 to 2021 from multicenter international databases were analyzed retrospectively. Patients with combined hepatocholangiocarcinoma (cases) were compared with 2 control groups of hepatocellular carcinoma or intrahepatic cholangiocarcinoma, sequentially matched using a propensity score based on 8 preoperative characteristics. Overall and disease-free survival were compared, and predictors of mortality and recurrence were analyzed with Cox regression after propensity score matching. RESULTS During the study period, 3,196 patients were included. Propensity score adjustment and 2 sequential matching processes produced a new cohort (n = 244) comprising 3 balanced groups was obtained (combined hepatocholangiocarcinoma = 56, intrahepatic cholangiocarcinoma = 66, and hepatocellular carcinoma = 122). Kaplan-Meier overall survival estimations at 1, 3, and 5 years were 67%, 45%, and 28% for combined hepatocholangiocarcinoma, 92%, 75%, and 55% for hepatocellular carcinoma, and 86%, 53%, and 42% for the intrahepatic cholangiocarcinoma group, respectively (P = .0014). Estimations of disease-free survival at 1, 3, and 5 years were 51%, 25%, and 17% for combined hepatocholangiocarcinoma, 63%, 35%, and 26% for the hepatocellular carcinoma group, and 51%, 31%, and 28% for the intrahepatic cholangiocarcinoma group, respectively (P = .19). Predictors of mortality were combined hepatocholangiocarcinoma subtype, metabolic syndrome, preoperative tumor markers alpha-fetoprotein and carbohydrate antigen 19-9, and satellite nodules, and recurrence was associated with satellite nodules rather than cancer subtype. CONCLUSION Despite data limitations, overall survival among patients with combined hepatocholangiocarcinoma was worse than both groups and closer intrahepatic cholangiocarcinoma, whereas disease-free survival was similar among the 3 groups. Future research on immunophenotypic profiling may hold more promise than traditional nonmodifiable clinical characteristics (as found in this study) in predicting recurrence or response to salvage treatments.
Collapse
Affiliation(s)
- Boris Amory
- Department of Digestive and Hepato-pancreatic-biliary Surgery, AP-HP, Hôpital Henri-Mondor, Paris Est Créteil University, UPEC, France; Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Claire Goumard
- Department of Hepatobiliary and Liver Transplantation Surgery, AP-HP, Hôpital Pitié Salpêtrière, CRSA, Sorbonne Université, Paris, France
| | - Alexis Laurent
- Department of Digestive and Hepato-pancreatic-biliary Surgery, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Paris Est Créteil University, UPEC, France; Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Serena Langella
- Department of General and Oncological Surgery, Ospedale Mauriziano, Torino, Italy
| | - Daniel Cherqui
- Center Hepato-Biliaire, AP-HP Paul Brousse Hospital, Paris-Saclay University, Villejuif, France
| | - Ephrem Salame
- Department of Digestive Surgery and Liver Transplantation, University Hospital of Tours, University of Tours, France; FHU Support, Tours, France
| | - Louise Barbier
- Department of Digestive Surgery and Liver Transplantation, University Hospital of Tours, University of Tours, France; FHU Support, Tours, France
| | - Olivier Soubrane
- Department of Digestive, Oncological, and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France
| | - Olivier Farges
- Department of HPB Surgery and Liver Transplantation, AP-HP Beaujon Hospital, University of Paris, Clichy, France
| | - Christian Hobeika
- Department of HPB Surgery and Liver Transplantation, AP-HP Beaujon Hospital, University of Paris, Clichy, France
| | - Takayuki Kawai
- Department of Surgery, Medical Research Institute, Kitano Hospital, Osaka and Graduate School of Medicine, Kyoto University, Japan
| | - Jean-Marc Regimbeau
- SSPC (Simplification of Surgical Patients Care) - Clinical Research Unit, University of Picardie Jules Verne, Amiens, France; Department of Digestive Surgery, Amiens University Medical Center, France
| | - François Faitot
- Service de Chirurgie Hépato-Biliaire et Transplantation Hépatique, Hôpital de Hautepierre, Strasbourg, France
| | - Patrick Pessaux
- Unité Chirurgie HBP, Pôle hépato-digestif Nouvel Hôpital Civil, Strasbourg, France; Institut of Viral and Liver Disease, Inserm U1110, Strasbourg, France
| | - Stéphanie Truant
- Department of Digestive Surgery and Transplantation, University Hospitals, Lille, France
| | - Emmanuel Boleslawski
- Department of Digestive Surgery and Transplantation, University Hospitals, Lille, France
| | - Astrid Herrero
- Department of HBP Surgery and Liver Transplantation, Montpellier University Hospital, University of Montpellier, France
| | - Jean-Yves Mabrut
- Croix Rousse University Hospital, Department of General Surgery and Liver Transplantation, Lyon, France; Cancer Research Center of Lyon, INSERM U1052, France
| | - Laurence Chiche
- Department of Hepato-Bilio-Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, Center Hospitalier Universitaire de Bordeaux, France; Inserm UMR 1312-Team 3 "Liver Cancers and Tumoral Invasion," Bordeaux Institute of Oncology, University of Bordeaux, France
| | - Marcello Di Martino
- HPB Unit, Department of General and Digestive Surgery, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Rami Rhaiem
- Department of Hepatobiliary, Pancreatic, and Digestive Surgery, Robert Debré University Hospital, Reims, France; University Reims Champagne-Ardenne, France
| | - Lilian Schwarz
- Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Rouen University Hospital, UNIROUEN, UMR 1245 INSERM, Normandie Rouen University, France
| | - Vivian Resende
- Federal University of Minas Gerais School of Medicine, Belo Horizonte, Brazil
| | - Julien Calderaro
- Université Paris Est Créteil, INSERM, IMRB, Créteil, France; Assistance Publique-Hôpitaux de Paris, Henri Mondor-Albert Chenevier University Hospital, Department of Pathology, Créteil, France; Inserm, U955, Team 18, Créteil, France
| | - Jérémy Augustin
- Université Paris Est Créteil, INSERM, IMRB, Créteil, France; Assistance Publique-Hôpitaux de Paris, Henri Mondor-Albert Chenevier University Hospital, Department of Pathology, Créteil, France; Inserm, U955, Team 18, Créteil, France
| | - Stefano Caruso
- Université Paris Est Créteil, INSERM, IMRB, Créteil, France; Assistance Publique-Hôpitaux de Paris, Henri Mondor-Albert Chenevier University Hospital, Department of Pathology, Créteil, France; Inserm, U955, Team 18, Créteil, France
| | - Daniele Sommacale
- Department of Digestive and Hepato-pancreatic-biliary Surgery, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Paris Est Créteil University, UPEC, Créteil, France; Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Stefan Hofmeyr
- Division of Surgery, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa
| | - Alessandro Ferrero
- Department of General and Oncological Surgery, Ospedale Mauriziano, Torino, Italy
| | - David Fuks
- Department of Hepato-Pancreatic-Biliary and Endocrine Surgery, Hopital Cochin, Assistance Publique-Hôpitaux de Paris, France; Université Paris Cité, France
| | - Eric Vibert
- Center Hepato-Biliaire, AP-HP Paul Brousse Hospital, Paris-Saclay University, Villejuif, France
| | - Guido Torzilli
- Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas Research Hospital - IRCCS, Humanitas University, Rozzano, Milan, Italy
| | - Olivier Scatton
- Department of Hepatobiliary and Liver Transplantation Surgery, AP-HP, Hôpital Pitié Salpêtrière, CRSA, Sorbonne Université, Paris, France
| | - Raffaele Brustia
- Department of Digestive and Hepato-pancreatic-biliary Surgery, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Paris Est Créteil University, UPEC, France; Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Créteil, France.
| |
Collapse
|
5
|
Li M, Fan Y, You H, Li C, Luo M, Zhou J, Li A, Zhang L, Yu X, Deng W, Zhou J, Zhang D, Zhang Z, Chen H, Xiao Y, Huang B, Wang J. Dual-Energy CT Deep Learning Radiomics to Predict Macrotrabecular-Massive Hepatocellular Carcinoma. Radiology 2023; 308:e230255. [PMID: 37606573 DOI: 10.1148/radiol.230255] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/23/2023]
Abstract
Background It is unknown whether the additional information provided by multiparametric dual-energy CT (DECT) could improve the noninvasive diagnosis of the aggressive macrotrabecular-massive (MTM) subtype of hepatocellular carcinoma (HCC). Purpose To evaluate the diagnostic performance of dual-phase contrast-enhanced multiparametric DECT for predicting MTM HCC. Materials and Methods Patients with histopathologic examination-confirmed HCC who underwent contrast-enhanced DECT between June 2019 and June 2022 were retrospectively recruited from three independent centers (center 1, training and internal test data set; centers 2 and 3, external test data set). Radiologic features were visually analyzed and combined with clinical information to establish a clinical-radiologic model. Deep learning (DL) radiomics models were based on DL features and handcrafted features extracted from virtual monoenergetic images and material composition images on dual phase using binary least absolute shrinkage and selection operators. A DL radiomics nomogram was developed using multivariable logistic regression analysis. Model performance was evaluated with the area under the receiver operating characteristic curve (AUC), and the log-rank test was used to analyze recurrence-free survival. Results A total of 262 patients were included (mean age, 54 years ± 12 [SD]; 225 men [86%]; training data set, n = 146 [56%]; internal test data set, n = 35 [13%]; external test data set, n = 81 [31%]). The DL radiomics nomogram better predicted MTM than the clinical-radiologic model (AUC = 0.91 vs 0.77, respectively, for the training set [P < .001], 0.87 vs 0.72 for the internal test data set [P = .04], and 0.89 vs 0.79 for the external test data set [P = .02]), with similar sensitivity (80% vs 87%, respectively; P = .63) and higher specificity (90% vs 63%; P < .001) in the external test data set. The predicted positive MTM groups based on the DL radiomics nomogram had shorter recurrence-free survival than predicted negative MTM groups in all three data sets (training data set, P = .04; internal test data set, P = .01; and external test data set, P = .03). Conclusion A DL radiomics nomogram derived from multiparametric DECT accurately predicted the MTM subtype in patients with HCC. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Chu and Fishman in this issue.
Collapse
Affiliation(s)
- Mengsi Li
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Yaheng Fan
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Huayu You
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Chao Li
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Ma Luo
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Jing Zhou
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Anqi Li
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Lina Zhang
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Xiao Yu
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Weiwei Deng
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Jinhui Zhou
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Dingyue Zhang
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Zhongping Zhang
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Haimei Chen
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Yuanqiang Xiao
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Bingsheng Huang
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| | - Jin Wang
- From the Departments of Radiology (M. Li, C.L., A.L., L.Z., Jinhui Zhou, D.Z., H.C., Y.X., J.W.) and Pathology (Jing Zhou), The Third Affiliated Hospital, Sun Yat-Sen University, No. 600 Tianhe Rd, Guangzhou, Guangdong, 510630, People's Republic of China; Medical AI Laboratory, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, People's Republic of China (Y.F., B.H.); Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China (H.Y.); Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China (M. Luo); and Department of Clinical Science, Philips Healthcare China, Shanghai, People's Republic of China (X.Y., W.D., Z.Z.)
| |
Collapse
|
6
|
Zhang Y, He D, Liu J, Wei YG, Shi LL. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics. World J Gastroenterol 2023; 29:2001-2014. [PMID: 37155523 PMCID: PMC10122786 DOI: 10.3748/wjg.v29.i13.2001] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 02/01/2023] [Accepted: 03/20/2023] [Indexed: 04/06/2023] Open
Abstract
BACKGROUND Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is closely related to aggressive phenotype, gene mutation, carcinogenic pathway, and immunohistochemical markers and is a strong independent predictor of early recurrence and poor prognosis. With the development of imaging technology, successful applications of contrast-enhanced magnetic resonance imaging (MRI) have been reported in identifying the MTM-HCC subtype. Radiomics, as an objective and beneficial method for tumour evaluation, is used to convert medical images into high-throughput quantification features that greatly push the development of precision medicine.
AIM To establish and verify a nomogram for preoperatively identifying MTM-HCC by comparing different machine learning algorithms.
METHODS This retrospective study enrolled 232 (training set, 162; test set, 70) hepatocellular carcinoma patients from April 2018 to September 2021. A total of 3111 radiomics features were extracted from dynamic contrast-enhanced MRI, followed by dimension reduction of these features. Logistic regression (LR), K-nearest neighbour (KNN), Bayes, Tree, and support vector machine (SVM) algorithms were used to select the best radiomics signature. We used the relative standard deviation (RSD) and bootstrap methods to quantify the stability of these five algorithms. The algorithm with the lowest RSD represented the best stability, and it was used to construct the best radiomics model. Multivariable logistic analysis was used to select the useful clinical and radiological features, and different predictive models were established. Finally, the predictive performances of the different models were assessed by evaluating the area under the curve (AUC).
RESULTS The RSD values based on LR, KNN, Bayes, Tree, and SVM were 3.8%, 8.6%, 4.3%, 17.7%, and 17.4%, respectively. Therefore, the LR machine learning algorithm was selected to construct the best radiomics signature, which performed well with AUCs of 0.766 and 0.739 in the training and test sets, respectively. In the multivariable analysis, age [odds ratio (OR) = 0.956, P = 0.034], alpha-fetoprotein (OR = 10.066, P < 0.001), tumour size (OR = 3.316, P = 0.002), tumour-to-liver apparent diffusion coefficient (ADC) ratio (OR = 0.156, P = 0.037), and radiomics score (OR = 2.923, P < 0.001) were independent predictors of MTM-HCC. Among the different models, the predictive performances of the clinical-radiomics model and radiological-radiomics model were significantly improved compared to those of the clinical model (AUCs: 0.888 vs 0.836, P = 0.046) and radiological model (AUCs: 0.796 vs 0.688, P = 0.012), respectively, in the training set, highlighting the improved predictive performance of radiomics. The nomogram performed best, with AUCs of 0.896 and 0.805 in the training and test sets, respectively.
CONCLUSION The nomogram containing radiomics, age, alpha-fetoprotein, tumour size, and tumour-to-liver ADC ratio revealed excellent predictive ability in preoperatively identifying the MTM-HCC subtype.
Collapse
Affiliation(s)
- Yang Zhang
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
| | - Dong He
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
| | - Jing Liu
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
| | - Yu-Guo Wei
- Precision Health Institution, General Electric Healthcare, Hangzhou 310014, Zhejiang Province, China
| | - Lin-Lin Shi
- Department of Gastroenterology, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou 310005, Zhejiang Province, China
| |
Collapse
|
7
|
Macrotrabecular-massive subtype-based nomogram to predict early recurrence of hepatocellular carcinoma after surgery. Eur J Gastroenterol Hepatol 2023; 35:505-511. [PMID: 36827535 PMCID: PMC9951792 DOI: 10.1097/meg.0000000000002525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
OBJECTIVES To analyze the predictive factors on early postoperative recurrence of hepatocellular carcinoma (HCC) and to establish a new nomogram to predict early postoperative recurrence of HCC. METHODS A retrospective analysis of 383 patients who had undergone curative resection between February 2012 and September 2020 in our center was performed. The Kaplan-Meier method was used for survival curve analysis. Univariate and multivariate Cox regression were performed to identify independent risk factors associated with early recurrence, and a nomogram for predicting early recurrence of HCC was established. RESULTS A total of 152/383 patients developed recurrence after surgery, of which 83 had recurrence within 1 year. Multivariate Cox regression analysis showed that preoperative alpha-fetoprotein level ≥400 ng/ml (P = 0.001), tumor diameter ≥5 cm (P = 0.009) and MVI (P = 0.007 and macrotrabecular-massive HCC (P = 0.003) were independent risk factors for early postoperative recurrence of HCC. The macrotrabecular-massive-based nomogram obtained a good C-index (0.74) for predicting early recurrence of HCC, and the area under the curve for predicting early recurrence was 0.767, which was better than the single American Joint Committee on Cancer T stage and Barcelona Clinic Liver Cancer stage. CONCLUSIONS The nomogram based on macrotrabecular-massive HCC can effectively predict early postoperative recurrence of HCC.
Collapse
|
8
|
Mulé S, Lawrance L, Belkouchi Y, Vilgrain V, Lewin M, Trillaud H, Hoeffel C, Laurent V, Ammari S, Morand E, Faucoz O, Tenenhaus A, Cotten A, Meder JF, Talbot H, Luciani A, Lassau N. Generative adversarial networks (GAN)-based data augmentation of rare liver cancers: The SFR 2021 Artificial Intelligence Data Challenge. Diagn Interv Imaging 2023; 104:43-48. [PMID: 36207277 DOI: 10.1016/j.diii.2022.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Accepted: 09/20/2022] [Indexed: 01/10/2023]
Abstract
PURPOSE The 2021 edition of the Artificial Intelligence Data Challenge was organized by the French Society of Radiology together with the Centre National d'Études Spatiales and CentraleSupélec with the aim to implement generative adversarial networks (GANs) techniques to provide 1000 magnetic resonance imaging (MRI) cases of macrotrabecular-massive (MTM) hepatocellular carcinoma (HCC), a rare and aggressive subtype of HCC, generated from a limited number of real cases from multiple French centers. MATERIALS AND METHODS A dedicated platform was used by the seven inclusion centers to securely upload their anonymized MRI examinations including all three cross-sectional images (one late arterial and one portal-venous phase T1-weighted images and one fat-saturated T2-weighted image) in compliance with general data protection regulation. The quality of the database was checked by experts and manual delineation of the lesions was performed by the expert radiologists involved in each center. Multidisciplinary teams competed between October 11th, 2021 and February 13th, 2022. RESULTS A total of 91 MTM-HCC datasets of three images each were collected from seven French academic centers. Six teams with a total of 28 individuals participated in this challenge. Each participating team was asked to generate one thousand 3-image cases. The qualitative evaluation was performed by three radiologists using the Likert scale on ten randomly selected cases generated by each participant. A quantitative evaluation was also performed using two metrics, the Frechet inception distance and a leave-one-out accuracy of a 1-Nearest Neighbor algorithm. CONCLUSION This data challenge demonstrates the ability of GANs techniques to generate a large number of images from a small sample of imaging examinations of a rare malignant tumor.
Collapse
Affiliation(s)
- Sébastien Mulé
- Medical Imaging Department, AP-HP, Henri Mondor University Hospital, Créteil 94000, France; INSERM, U955, Team 18, Créteil 94000, France.
| | - Littisha Lawrance
- Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay, Inserm, CNRS, CEA, BIOMAPS, UMR 1281, Université Paris-Saclay, Villejuif 94800, France
| | - Younes Belkouchi
- Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay, Inserm, CNRS, CEA, BIOMAPS, UMR 1281, Université Paris-Saclay, Villejuif 94800, France; OPIS-Optimisation Imagerie et Santé, Inria, CentraleSupélec, CVN-Centre de Vision Numérique, Université Paris-Saclay, Gif-Sur-Yvette 91190, France
| | - Valérie Vilgrain
- Department of Radiology, APHP, University Hospitals Paris Nord Val de Seine, Hôpital Beaujon, Clichy 92110, France; CRI INSERM, Université Paris Cité, Paris 75018, France
| | - Maité Lewin
- Department of Radiology, AP-HP Hôpital Paul Brousse, Villejuif 94800, France; Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre 94270, France
| | - Hervé Trillaud
- CHU de Bordeaux, Department of Radiology, Université de Bordeaux, Bordeaux 33000, France
| | - Christine Hoeffel
- Department of Radiology, Reims University Hospital, Reims 51092, France; CRESTIC, University of Reims Champagne-Ardenne, Reims 51100, France
| | - Valérie Laurent
- Department of Radiology, Nancy University Hospital, University of Lorraine, Vandoeuvre-ls-Nancy 54500, France
| | - Samy Ammari
- Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay, Inserm, CNRS, CEA, BIOMAPS, UMR 1281, Université Paris-Saclay, Villejuif 94800, France; Department of Imaging, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France
| | - Eric Morand
- Centre National d'Etudes Spatiales-CNES, Centre Spatial de Toulouse, Toulouse 31401 CEDEX 9 University, France
| | - Orphée Faucoz
- Centre National d'Etudes Spatiales-CNES, Centre Spatial de Toulouse, Toulouse 31401 CEDEX 9 University, France
| | - Arthur Tenenhaus
- CentraleSupélec, Laboratoire des Signaux et Systèmes, Université Paris-Saclay, Gif-sur-Yvette 91190, France
| | - Anne Cotten
- Department of Musculoskeletal Radiology, Centre de Consultations Et D'imagerie de L'appareil Locomoteur, Lille 59037, France; Lille University School of Medicine, Lille, France
| | - Jean-François Meder
- Department of Neuroimaging, Sainte-Anne Hospital, Paris 75013 University, France; Université Paris Cité, Paris 75006, France
| | - Hugues Talbot
- OPIS-Optimisation Imagerie et Santé, Inria, CentraleSupélec, CVN-Centre de Vision Numérique, Université Paris-Saclay, Gif-Sur-Yvette 91190, France
| | - Alain Luciani
- Medical Imaging Department, AP-HP, Henri Mondor University Hospital, Créteil 94000, France; INSERM, U955, Team 18, Créteil 94000, France
| | - Nathalie Lassau
- Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay, Inserm, CNRS, CEA, BIOMAPS, UMR 1281, Université Paris-Saclay, Villejuif 94800, France; Department of Imaging, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France
| |
Collapse
|